Drug Profile
Sarecycline - Almirall S.A./Paratek Pharmaceuticals
Alternative Names: P 0005672; P 005672; Seysara; WC-3035Latest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Paratek Pharmaceuticals
- Developer Actavis; Almirall S.A.; Paratek Pharmaceuticals
- Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines; Vascular disorder therapies
- Mechanism of Action Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acne vulgaris
- Discontinued Rosacea